

Bubs aims for China Food and Drug registration

08 June 2018 | News

Bubs Australia (ASX:BUB) has entered into a binding production agreement with Australia Deloraine Dairy as a vital step towards reaching China Food and Drug Administration (CFDA) registration.



Bubs Australia Chairman, Dennis Lin says there may be an growing demand for goat milk based infant method in China, specifically in mother and baby shops.

Bubs Australia (ASX:BUB) has entered into a binding production agreement with Australia Deloraine Dairy as a vital step towards reaching China Food and Drug Administration (CFDA) registration.

Australia Deloraine Dairy is one of best 15 licenced facilities in Australia authorised by way of Certification and Accreditation administration of the people's Republic of China (CNCA) to produce toddler method products eligible for importation into China, underneath the regulatory necessities administered by way of CFDA.

Bubs Australia Chairman, Dennis Lin says there may be an growing demand for goat milk based infant method in China, specifically in mother and baby shops.

Stocks in Bubs Australia (ASX:BUB) closed flat at 80c yesterday.